Usona completes FDA submission of psilocybin NDA for major depressive disorder
Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
Usona Institute has completed its submission of a new drug applicationNDAA new drug application, the formal request asking the FDA to approve a new medicine for sale in the United States.Open the glossary to the US Food and Drug AdministrationFDAThe Food and Drug Administration, the United States regulator of medicines, medical devices and food.Open the glossary for its psilocybin candidate for major depressive disorder.
Key facts
- Kind of item
- Regulator decisions
- Compound
- Psilocybin
- Condition
- Depression
- Organisation
- Usona Institute
- Regulator
- FDA (United States)
- Jurisdiction
- United States
- Source
- Psychedelic Alpha (psychedelicalpha.com)
- Published
- Original
- Read it at psychedelicalpha.com
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: Psychedelic Alpha · psychedelicalpha.com
Connected to
- Kind of item
- Regulator decisions
- Compound
- Psilocybin
- Condition
- Depression
- Organisation
- Usona Institute
- Regulator
- FDA (United States)
- Jurisdiction
- United States